Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company will present at upcoming investor and scientific conferences.

Investor Conferences
  • Jefferies 2014 Global Healthcare Conference on Thursday, Nov. 20 at 12:20 p.m. GMT in London
  • 7th Annual 2014 Deutsche Bank BioFEST on Monday, Dec. 1, at 11:35 a.m. EST in Boston
  • 26th Annual Piper Jaffray Healthcare Conference on Wednesday, Dec. 3, at 3 p.m. EST in New York

Investors may access a live and archived audio webcast of these presentations on the Company's website at

Scientific Conferences
  • 15th Annual EuroTIDES meeting on Wednesday, Nov. 19, at 5 p.m. CET in Berlin

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.

For more information please visit, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit

Source: Arrowhead Research Corporation

Copyright Business Wire 2010